Breast Cancer Survivors Find Support on Twitter Oct 30, 2012 As Eureka wraps up its series on cancer research innovation in honor of Breast Cancer Awareness Month, we wanted to point out how the cancer patient community is using social media to unite and share resources. Improving Cancer Drugs with Animal “Avatars” Oct 22, 2012 Patient-derived tumor xenografts show promise in the early evaluation of potential cancer therapies. Magic Bullets: The Next Evolution in Targeted Cancer Therapy Oct 16, 2012 New ‘armed antibodies’ represent proverbial magic bullets–envisioned by a Nobel Laureate 100 years ago–killing tumors with greater efficacy and fewer side effects. Transgenic Mouse Models as Alternatives to the 2-Year Mouse Bioassay Oct 08, 2012 Formerly regarded as an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay. Treatment Advances for Acute Lymphoblastic Leukemia Increase Survival Rates Oct 01, 2012 Mortality rates for this most common childhood cancer are dropping due to remarkable advances in diagnosis and treatment.
Breast Cancer Survivors Find Support on Twitter Oct 30, 2012 As Eureka wraps up its series on cancer research innovation in honor of Breast Cancer Awareness Month, we wanted to point out how the cancer patient community is using social media to unite and share resources.
Improving Cancer Drugs with Animal “Avatars” Oct 22, 2012 Patient-derived tumor xenografts show promise in the early evaluation of potential cancer therapies.
Magic Bullets: The Next Evolution in Targeted Cancer Therapy Oct 16, 2012 New ‘armed antibodies’ represent proverbial magic bullets–envisioned by a Nobel Laureate 100 years ago–killing tumors with greater efficacy and fewer side effects.
Transgenic Mouse Models as Alternatives to the 2-Year Mouse Bioassay Oct 08, 2012 Formerly regarded as an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay.
Treatment Advances for Acute Lymphoblastic Leukemia Increase Survival Rates Oct 01, 2012 Mortality rates for this most common childhood cancer are dropping due to remarkable advances in diagnosis and treatment.
